NCT05402020View on ClinicalTrials.gov

Effectiveness of Tiotropium + Olodaterol Versus Inhaled Corticosteroids (ICS) + Long-acting β2-agonists (LABA) Among COPD Patients in Taiwan

CompletedOBSERVATIONAL
Enrollment

17,018

Participants

Timeline

Start Date

September 30, 2022

Primary Completion Date

February 13, 2023

Study Completion Date

February 13, 2023

Conditions
Pulmonary Disease, Chronic Obstructive
Interventions
DRUG

Tiotropium (Tio)

Tiotropium (Tio)

DRUG

Inhaled corticosteroids (ICS)

Inhaled corticosteroids (ICS)

DRUG

Olodaterol (Olo)

Olodaterol (Olo)

DRUG

Long-acting β2-agonists (LABA)

Long-acting β2-agonists (LABA)

Trial Locations (1)

100225

National Tawain University Hospital, Taipei

Sponsors
All Listed Sponsors
lead

Boehringer Ingelheim

INDUSTRY

NCT05402020 - Effectiveness of Tiotropium + Olodaterol Versus Inhaled Corticosteroids (ICS) + Long-acting β2-agonists (LABA) Among COPD Patients in Taiwan | Biotech Hunter | Biotech Hunter